Coloma Jason V 4

What Happened

• Jason V. Coloma, CEO of Maze Therapeutics, sold a total of 34,501 shares in three open-market transactions on July 1, 2026, generating about $1,034,253 in proceeds. The reported lots were: 30,311 shares at a weighted average price of $29.95 ($907,921), 2,593 shares at $29.98 ($77,726), and 1,597 shares at $30.44 ($48,606). All transactions are sales (S).

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 2, 2026 (within the typical 2-business-day window).
• Reported totals: 34,501 shares sold for approximately $1,034,253.
• Price details: the filing reports weighted-average prices; individual execution prices ranged roughly from $29.38 to $30.49 per share across the lots (full breakdowns available from the filer/SEC on request).
• Plan / holding notes:
  • At least one sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Coloma on Feb 6, 2026.
  • Some of the securities sold were held directly by trusts for which Coloma and his spouse are co-trustees (The Coloma 2021 Irrevocable Trust and the Coloma Family Trust).
• Shares owned after the transactions are not specified in the provided excerpt.

Context

• These are open-market sales, often routine and sometimes executed under prearranged 10b5-1 plans; such sales do not by themselves indicate management’s view of the company’s prospects. The filing’s weighted-average pricing and footnotes mean the reported prices represent multiple executions across the ranges noted.